Been a while…update/ recapThis stock price & corporate progress are so far out of phase.
First a quest was asked abtount Brad.
That would be Brad Tompson the founding CEO/ president before existing Dr. Matt Cofee
Matt is the last existing of founding senior mangement.
He discovered Pela & filed most of the existing in- place patents....for use with various cancer treatments.
I held shares during the very old days. Was out for quite a few years.
bought back in when Matt was promoted & replaced Brad T.
ironically very soon before the A.N China regional licensing deal.
Few appreciate, there is up- to $60m -$80m of milestone payments to Onc, once MBc phase 3 starts.
Plus perpetual royalties, once Pela gets to market.
Moving forward to recent times.
About a month ago, on the compelling results from a phase 2 trial ,alongside Roche. Treating pancreatic cancer, Onc was granted FDA fast track approval & then invited by PanCan to assist with a phase 3 trial.
Now they have two phase 3 ready opportunities.
They announced " within 90 days", will announce further details.
Since Onc can not afford a phase 3 trial alone. The options are.
1. A licensing deal, most likely with Roche.
2. A share exchange partnership, Roche, Pfizer, Incyte, or Merck. All of which they have on going trials in other cancer types or sub types.
3. A complete buy- out. ( see #2 above).
not to mention they are " in discussions " with regards to CAR- t results
All of the above points to a SP much greater than we are now.
Not additive, but many multiples.
all the best everyone
BTW, I read there has been a 400% increase in short volume.
All we need is a decent update & ooch...short squeeze.